The FDA advises health-care professionals to follow up with patients for whom they administered an injectable product purchased from or produced by NECC.
Welcome to ModernMedicine
The FDA has approved ocriplasmin (Jetrea, ThromboGenics) for the treatment of symptomatic vitreomacular adhesion (VMA).
A Canadian trial including 120 subjects is investigating the safety and efficacy of an acrylic, foldable, single-piece, angle-supported phakic IOL (AcrySof Cachet, Alcon).
FCI Ophthalmics has received 510(k) clearance for a pushed monocanalicular nasolacrimal intubation stent (Masterka).
The FDA has approved cysteamine ophthalmic solution (Cystaran, Sigma-Tau Pharmaceuticals) 0.44% for corneal cystine crystal accumulation in patients with cystinosis.
The FDA has cleared the additional indication of corneal flap creation in refractive surgical procedures for a femtosecond laser platform (LenSx Laser, Alcon).
A video description of Cataract Surgery: Telling It Like It Is!, cataract meeting organized by Robert H. Osher, MD.
To clarify whether total intracranial CSF volume increases in IIH, researchers prospectively studied MRI-derived measures of total cranial, ventricular, and extraventricular CSF volumes in patients with IIH and controls. Results showed that the extraventricular CSF space was significantly greater in the patient group versus the controls. The ventricular volume was the same between the two groups.
A phase IIa proof of concept study of a novel rho-kinase (ROCK) inhibitor (AMA0076, Amakem NV) is now underway in patients with glaucoma and ocular hypertension.
Aflibercept (Eylea, Regeneron) has gained FDA approval for treatment of macular edema following CRVO and recommendation for approval by the CHMP for treatment of neovascular AMD.